Business
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON, March 31, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.
About this update from Adicet Bio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":288,"url":"https://media.zenfs.com/en/business-wire.com/2834b44c822e0775682db9203fb8d2ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YYtCQbH_HPCLlLSOmqDNEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2834b44c822e0775682db9203fb8d2ce","width":480,"height":288}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif. & BOSTON, March 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.","length":433,"tagName":"p"},{"type":"text","content":"Details of the event are as follows:Panel: "CAR T Approaches in the Autoimmune Space"Date: Monday, April 7, 2025Time: 3:00 p.m. ET","length":143,"tagName":"p"},{"type":"text","content":"About Adicet Bio, Inc.","length":22,"tagName":"p"},{"type":"text","content":"Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.","length":414,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Adicet Bio, Inc. Investor and Media Contacts","length":45,"tagName":"p"},{"type":"text","content":"Investors: Anne [email protected]","length":49,"tagName":"p"},{"type":"text","content":"Janhavi MohitePrecision [email protected]","length":71,"tagName":"p"},{"type":"text","content":"Media: Kerry Beth [email protected]","length":44,"tagName":"p"}]